Supplementary Material

# Supplementary Data

## Supplementary Data 1

**PubMed**

1. "Carcinoma, Hepatocellular"[Mesh] OR "Liver Neoplasms"[Mesh]

2. carcinoma\* OR cancer\* OR tumor\* OR malign\* OR neoplasm\*

3. Liver\* OR hepatic\* OR hepato\*

4. 1 OR (2 AND 3)

5. "Chemoembolization, Therapeutic"[Mesh] OR Chemoemboli\* OR emboli\* OR TACE OR TAE OR transarterial OR transcatheter

6. Lenvatinib OR Lenvaxen OR Lenvima

7. Sorafenib OR Nexavar

**Cochrane**

#1 MeSH descriptor: [Carcinoma, Hepatocellular] explode all trees

#2 MeSH descriptor: [Liver Neoplasms] explode all trees

#3 (liver\*) OR (hepatic\*) OR (hepato\*)

#4 (carcinoma\*) OR (cancer\*) OR (tumor\*) OR (malign\*) AND (neoplasm\*)

#5 #3 AND #4

#6 #1 OR #2 OR #5

#7 MeSH descriptor: [Chemoembolization, Therapeutic] explode all trees

#8 (Chemoemboli\*) OR (emboli\*) OR (TACE) OR (TAE) OR (transarterial) (Word variations have been searched)

#9 (transcatheter) (Word variations have been searched)

#10 (Lenvatinib) OR (Lenvaxen) OR (Lenvima) (Word variations have been searched)

#11 (sorafenib) OR (Nexavar) (Word variations have been searched)

#12 #7 OR #8 OR #9

#13 #6 AND #10 AND #11 AND #12

**Embase**

1. liver cancer.mp. or exp liver cancer/

2. hepatocellular carcinoma.mp. or exp liver cell carcinoma/

3. (liver\* or hepatic or hepato\*).mp.

4. (carcinoma\* or cancer\* or tumor\* or malign\* or neoplasm\*).mp.

5. 1 or 2 or (3 and 4)

6. Chemoembolization.mp. or exp chemoembolization/

7. (Chemoemboli\* or emboli\* or TACE or TAE or transarterial or transcatheter).mp.

8. 6 or 7

9. Lenvatinib.mp. or exp lenvatinib/

10. (Lenvaxen or Lenvima).mp.

11. sorafenib.mp. or exp sorafenib/

12. Nexavar.mp.

13. 9 or 10

14. 11 or 12

15. 5 and 8 and 13 and 14

# Supplementary Figure

## Supplementary Figure 1

****

**Supplementary Figure 1.** Summary of forest plots of grade 3/4 adverse events. HFSR, hand–foot–skin reaction; TACE, transarterial chemoembolization; LEN, lenvatinib; SOR, sorafenib.